Meropenem Hikma

Meropenem, the active ingredient in Meropenem Hikma, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It treats severe bacterial infections, including intra‑abdominal, urinary tract, meningitis, pneumonia, and sepsis, in hospitalized adult patients. It is indicated for use in patients with complicated intra‑abdominal infections, complicated urinary tract infections, bacterial meningitis, hospital‑acquired pneumonia, and sepsis, where broad‑spectrum coverage against Gram‑negative, Gram‑positive and anaerobic organisms is required.

GNH USA supplies Meropenem Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, health systems and clinics worldwide.

Meropenem is a carbapenem antibiotic used for serious bacterial infections across several organ systems. - Complicated intra‑abdominal infections: provides broad‑spectrum bacterial eradication to resolve infection and prevent progression. - Complicated urinary tract infections: achieves bacterial clearance in resistant uropathogens. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat meningitic pathogens. - Hospital‑acquired pneumonia: targets multidrug‑resistant organisms causing lower respiratory infection. - Sepsis: offers rapid bactericidal activity to support systemic infection control.

Like all antibiotics, meropenem may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset that usually resolves without intervention. - Diarrhea: may be watery, occurring during therapy and often self‑limiting. - Headache: transient cranial discomfort reported by some patients. - Rash: mild skin erythema or pruritus that typically subsides after discontinuation.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction requiring immediate emergency care. - Seizures: especially in patients with renal dysfunction or pre‑existing central nervous system disorders. - Clostridioides difficile colitis: severe inflammation of the colon that can cause profuse diarrhea and abdominal pain. - Elevated liver enzymes: indicating hepatic stress; monitor liver function tests during prolonged therapy.

When using meropenem, clinicians should observe several safety measures to minimize risks. - Renal function: adjust dose in patients with impaired kidney function. - Hypersensitivity: avoid in individuals with known carbapenem or β‑lactam allergy. - Seizure risk: monitor neurologic status, especially in patients with CNS disorders. - Antibiotic stewardship: limit use to confirmed bacterial infections to prevent resistance. - Concomitant nephrotoxic drugs: use caution when combined with other renal‑toxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concurrent use may reduce valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential; monitor renal function. - Loop diuretics: may enhance nephrotoxicity; assess kidney parameters. - Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation status.